UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at Hold; Royalty Burden High
Stifel Nicolaus initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Hold rating.
Stifel Nicolaus noted, "Infinity's phosphoinositide-3-kinase (PI3K) inhibitor, IPI-145, has the potential to be a best-in-class drug for one of the most exciting targets in oncology and inflammation treatment. Preclinical data for IPI-145 as well as data from other drugs in development validate the PI3K target in our opinion as one that will provide strong efficacy in tumor resistance and inflammation reduction, while retaining a favorable safety profile. IPI-145 is the only dual PI3K delta and gamma inhibitor currently in clinical trials."
Infinity Pharmaceuticals closed at $17.74 on Thursday.
Latest Ratings for INFI
|Jun 2016||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
|Jun 2016||Wells Fargo||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.